SPHRF Stock Chart & Stats
$0.47
$0.04(8.49%)
At close: 4:00 PM EDT
$0.47
$0.04(8.49%)
Day’s Range― - ―
52-Week Range$0.10 - $0.58
Previous CloseN/A
Volume1.00K
Average Volume (3M)71.00
Market Cap
$247.74M
Enterprise Value$284.34
Total Cash (Recent Filing)$11.02M
Total Debt (Recent Filing)$707.00K
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding477,054,960
10 Day Avg. Volume48
30 Day Avg. Volume71
Financial Highlights & Ratios
PEG Ratio1.43
Price to Book (P/B)21.33
Price to Sales (P/S)24.38
P/FCF Ratio-84.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)$17.22M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe 145.3% reported revenue-growth figure and A$12.1m 2026 revenue indicate stronger commercial receipts. If sustained, a larger revenue base can improve operating leverage and support monetisation of the company’s platform and product portfolio.
Lower Financial LeverageThe substantial reduction in debt lowers interest and refinancing exposure, giving Starpharma greater flexibility to fund development and commercialisation. Conservative leverage is a durable balance-sheet advantage while the company works toward profitability.
Improved Cash BurnAlthough cash flow remains negative, the marked improvement in 2026 suggests tighter spending or better operating performance. Continued progress could extend the funding runway and reduce the scale of capital required before the business reaches self-funding.
Bears Say
Persistent Operating LossesOngoing EBIT, EBITDA and net losses show that gross profit has not yet translated into a sustainable operating model. Without meaningful cost leverage or higher-margin commercial income, profitability may remain dependent on future partnering or funding.
Negative Free Cash FlowPersistent negative operating and free cash flow means the company is not self-funding its research and commercial activities. Even with improved 2026 burn, continued outflows could require additional financing and constrain investment in pipeline development.
Eroding Equity BaseThe sharp decline in equity, alongside shrinking total assets, reflects the cumulative effect of losses and cash consumption. It reduces financial resilience and limits flexibility to absorb development setbacks or fund expansion without dilution or other capital support.
Starpharma Holdings Limited News
SPHRF FAQ
What was Starpharma Holdings Limited’s price range in the past 12 months?
Starpharma Holdings Limited lowest stock price was $0.10 and its highest was $0.58 in the past 12 months.
What is Starpharma Holdings Limited’s market cap?
Starpharma Holdings Limited’s market cap is $247.74M.
When is Starpharma Holdings Limited’s upcoming earnings report date?
Starpharma Holdings Limited’s upcoming earnings report date is Mar 02, 2027 which is in 179 days.
How were Starpharma Holdings Limited’s earnings last quarter?
Starpharma Holdings Limited released its earnings results on Aug 25, 2026. The company reported -$0.014 earnings per share for the quarter.
Is Starpharma Holdings Limited overvalued?
According to Wall Street analysts Starpharma Holdings Limited’s price is currently Overvalued.
Does Starpharma Holdings Limited pay dividends?
Starpharma Holdings Limited does not currently pay dividends.
What is Starpharma Holdings Limited’s EPS estimate?
Starpharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Starpharma Holdings Limited have?
Starpharma Holdings Limited has 477,054,960 shares outstanding.
What happened to Starpharma Holdings Limited’s price movement after its last earnings report?
Starpharma Holdings Limited reported an EPS of -$0.014 in its last earnings report. Following the earnings report the stock price went down -0.383%.
Which hedge fund is a major shareholder of Starpharma Holdings Limited?
Currently, no hedge funds are holding shares in SPHRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Starpharma Holdings Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
SPHRF Sentiment 88%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth $221.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
398.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.92%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Starpharma Holdings Limited
Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis. The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform. This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer. The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies. Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.
Technical Analysis
Immutep Ltd
―
Dimerix Limited
―
AnteoTech Ltd
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―
Ownership Overview
1.16% Insiders
0.04% Mutual Funds
<0.01% Other Institutional Investors
98.77% Public Companies and
Individual Investors